Literature DB >> 36180698

Why Are We Still Cloning Melatonin Receptors? A Commentary.

Célia Gautier1, Isabelle Theret1, Giulia Lizzo1, Gilles Ferry1, Sophie-Pénélope Guénin1, Jean A Boutin2,3.   

Abstract

Cloning may seem to be a view from the past. The time before software, computers and AI were invented. It seems to us worth discussing these points in view of our favorite target: the melatoninergic system. In a few stances, it might be important to point out that even in the new era of dry science, there is still a need to experiment and to prove at the bench that our in silico assertions are right. Most of the living animals express to some extend the melatonin receptors. Some of these animal genomes were completely or partially sequenced, and it is tempting to extract from this huge information the sequence(s) of our favorite genes (MLT receptors). Then, why bother cloning, as opposed to simply built the gene and express it in a host cell? Because the genetic boundaries of the expressed sequence(s) are not 100% sure. Because the melatonin receptor gene(s) comprise a first exon 25,000 base pair far from the second one and the limits between this Ex1 and In1-as between In1 and Ex2-are subject to changes that might have a huge impact on the biochemical properties of the receptor, once expressed. Because a receptor is a biochemical entity with characteristics that are important for the functioning of this particular pathway, and more generally, for the functioning of life.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cloning; Commentary; Melatonin receptors

Mesh:

Substances:

Year:  2022        PMID: 36180698     DOI: 10.1007/978-1-0716-2593-4_29

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  44 in total

1.  The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization.

Authors:  Angélique Levoye; Julie Dam; Mohammed A Ayoub; Jean-Luc Guillaume; Cyril Couturier; Philippe Delagrange; Ralf Jockers
Journal:  EMBO J       Date:  2006-06-15       Impact factor: 11.598

Review 2.  Update on melatonin receptors: IUPHAR Review 20.

Authors:  Ralf Jockers; Philippe Delagrange; Margarita L Dubocovich; Regina P Markus; Nicolas Renault; Gianluca Tosini; Erika Cecon; Darius P Zlotos
Journal:  Br J Pharmacol       Date:  2016-08-08       Impact factor: 8.739

Review 3.  Quinone reductase 2 as a promising target of melatonin therapeutic actions.

Authors:  Jean A Boutin
Journal:  Expert Opin Ther Targets       Date:  2015-10-14       Impact factor: 6.902

Review 4.  Arylalkylamine N-acetyltransferase: "the Timezyme".

Authors:  David C Klein
Journal:  J Biol Chem       Date:  2006-12-12       Impact factor: 5.157

5.  Melatonin from cerebrospinal fluid but not from blood reaches sheep cerebral tissues under physiological conditions.

Authors:  C Legros; D Chesneau; J A Boutin; C Barc; B Malpaux
Journal:  J Neuroendocrinol       Date:  2014-03       Impact factor: 3.627

Review 6.  Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

Authors:  R Jockers; P Maurice; J A Boutin; P Delagrange
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

Review 7.  Cellular mechanisms of melatonin action.

Authors:  J Vanecek
Journal:  Physiol Rev       Date:  1998-07       Impact factor: 37.312

Review 8.  Structural insights into melatonin receptors.

Authors:  Benjamin Stauch; Linda C Johansson; Vadim Cherezov
Journal:  FEBS J       Date:  2019-11-23       Impact factor: 5.542

9.  GPR50 is the mammalian ortholog of Mel1c: evidence of rapid evolution in mammals.

Authors:  Laurence Dufourny; Anthony Levasseur; Martine Migaud; Isabelle Callebaut; Pierre Pontarotti; Benoit Malpaux; Philippe Monget
Journal:  BMC Evol Biol       Date:  2008-04-09       Impact factor: 3.260

Review 10.  Melatonin receptor genes in vertebrates.

Authors:  Di Yan Li; David Glenn Smith; Rüdiger Hardeland; Ming Yao Yang; Huai Liang Xu; Long Zhang; Hua Dong Yin; Qing Zhu
Journal:  Int J Mol Sci       Date:  2013-05-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.